NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
MedImmune LLC
Institut du Cancer de Montpellier - Val d'Aurelle
University of Michigan Rogel Cancer Center
Roswell Park Cancer Institute
National Cancer Institute (NCI)
AstraZeneca
Takeda
Eli Lilly and Company
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb
Bristol-Myers Squibb
NantCell, Inc.
Hoffmann-La Roche
Sotio Biotech Inc.
Alaunos Therapeutics
BioNTech SE
Baylor College of Medicine
Vedanta Biosciences, Inc.
Eisai Inc.
Incyte Corporation
University of Pennsylvania
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emory University
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Bristol-Myers Squibb
University of Chicago
Mayo Clinic
Nektar Therapeutics
Triumvira Immunologics, Inc.
Hoffmann-La Roche
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
Aprea Therapeutics
Hutchmed
Precision Biologics, Inc
Thomas Jefferson University
Precirix
Thomas Jefferson University
Menarini Group
NuCana plc
Imugene Limited
HiberCell, Inc.
MacroGenics
Imperial College London
Cardiff Oncology
Intensity Therapeutics, Inc.